Russell Investments Group
TCRR

Russell Investments Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Russell Investments Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,448
Closed -$208K – 3330
2021
Q1 		$208K Hold
9,448
– – ﹤0.01% 2815
2020
Q4 		$292K Sell
9,448
-2,588
-22% -$65.4K ﹤0.01% 2640
2020
Q3 		$243K Buy
12,036
+9,448
+365% +$166K ﹤0.01% 2700
2020
Q2 		$39K Buy
+2,588
New +$29.9K ﹤0.01% 3008

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Russell Investments Group's TCRR Position: Q2 2021 in Review

Russell Investments Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2021, closing a stake of 9,448 shares — an estimated $208K sold.

Russell Investments Group first reported a position in TCRR in Q2 2020 and held it in 4 quarters. The position peaked at $292K in Q4 2020. 119 funds tracked by Wall St. Rank hold TCRR as of Q2 2021.

  • Russell Investments Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Russell Investments Group sold 9,448 TCR2 Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $208K.
  • Russell Investments Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Russell Investments Group's TCR2 Therapeutics Inc. Common Stock position peaked at $292K in Q4 2020.
  • 119 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2021.

Based on Russell Investments Group's 13F filing for Q2 2021, filed 4 Aug 2021.